The Reality Check of Gene Editing: Biotech's Narrow Bridge in 2026Global Report·2 hours agoCCXI-0.74%BEAM+0.44%
Biotech Maturation Signaled by Late-Stage Approvals and Gene Editing MilestonesGlobal Report·4 hours agoRVMD-0.11%EDIT-0.35%
The US Biotech Bloodbath: Gene Editing Bets, AI Pivots, and Chapter 11 SurprisesGlobal Report·Sep 16 at 10:13 AMEDIT-0.35%EYPT+1.74%
Weekly Recap | Editas Medicine -16.41%, consensus target above spotWeekly Review·Sep 12 at 08:10 AMEDIT-0.35%
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing TherapyMarket Beat·Sep 12 at 01:01 AMEDIT-0.35%
Editas Medicine EVP, Chief Medical Officer Daniel Ory files initial beneficial ownership statementPUBT·Sep 9 at 08:25 PMEDIT-0.35%
Editas grants new CMO Daniel Ory stock options for 950,000 shares at USD 3.03 eachPUBT·Sep 9 at 01:02 PMEDIT-0.35%
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401Market Beat·Sep 9 at 11:02 AMEDIT-0.35%
Cross-Border Capital Shifts: Macro Tensions from US Tech to EM HedgesGlobal Report·Sep 8 at 10:19 AMUCTT+1.06%KLAR-0.58%
Editas Medicine to Participate in Upcoming Investor ConferencesUnusual Whales·Sep 1 at 01:02 PMEDIT-0.35%
Pentagon Funding for Mining and Biotech Advances: Inside This Week's Equity MovesGlobal Report·Sep 1 at 10:13 AMEDIT-0.35%TMQ+2.10%
Regulators Signal Clear Path: Gene Therapies Advance to CommercializationGlobal Report·Aug 25 at 10:12 AMEDIT-0.35%NTLA+0.94%
Asana’s USD 12,000 AI Experiment and the Messy Reality of Tech Infrastructure in 2026Global Report·Aug 20 at 10:16 AMASAN-0.05%EDU-0.22%
